Skip to main content
. 2016 Dec 9;10(2):91–101. doi: 10.1177/1756285616679369

Figure 1.

Figure 1.

Concomitant treatment at baseline and after two-years-treatment. Six patients had two or more substances for pre-treatment (A) which explains the n- number > 21. One patient had a rapid progression of disease and treatment was adjusted several times also using off-label therapies like fumarates. In the end, this patient died one year after observation period.